Updates are available Correction dated 2025-04-04
Click to view Correction: https://doi.org/10.1007/s40120-025-00731-z
-
Authors
Stimming, Erin Furr
Claassen, Daniel O.
Sen, Ginny P. https://orcid.org/0009-0004-7997-0954
Klepitskaya, Olga
Serbin, Michael
Kim, Hyunwoo
Hinton, Sean C.
Haubenberger, Dietrich
-
Funding
Funding for this research was provided by:
Neurocrine Biosciences
- License Information
-
More Information
Article History
Received: 21 October 2024
Accepted: 16 December 2024
First Online: 15 January 2025
Change Date: 29 March 2025
Change Type: Update
Change Details: The original online version of this article was revised to correct two sentences.
Change Date: 4 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40120-025-00731-z
Declarations
:
: Dr. Dietrich Haubenberger, Dr. Olga Klepitskaya, Dr. Sean C. Hinton, Ginny P. Sen, and Dr. Michael Serbin are full-time employees of Neurocrine Biosciences, Inc. Dr. Haubenberger receives publishing royalties from Oxford University Press. Hyunwoo Kim is a contract employee of Neurocrine Biosciences, Inc. Dr. Erin Furr Stimming receives research funding from CHDI, HDSA, Prilennia, University of Iowa/NIH, UniQure, HSG/NBI, and Sage Therapeutics, royalties from McGraw Hill and Oxford Publishing, and is a consultant/application reviewer for Teva Pharmaceuticals and MJFF. Dr. Claassen has received research support from the NIH/NINDS/NIA/NICHD/NCCIH, Department of Defense, Griffin Family Foundation, and Huntington Disease Society of America; he has received pharmaceutical grant support from AbbVie, Alterity, Acadia, Biogen, BMS, Cerecour, Eli Lilly, Genentech-Roche, Lundbeck, Jazz Pharmaceuticals, Neurocrine, Teva Neuroscience, Wave Life Sciences, UniQure, and Vaccinex. He has received personal fees for consulting from Acadia, Alterity, Adamas, Anexon, Ceruvel, Lundbeck, Neurocrine, Spark, Uniqure, and Teva Neuroscience.The authors declare that there are no additional disclosures to report.
: Data used in this work were generously provided by participants in the Enroll-HD study and made available by CHDI Foundation, Inc. Enroll-HD is a global clinical research platform designed to facilitate clinical research in HD. Core datasets are collected annually from all research participants as part of this multi-center, longitudinal, observational study. Data are monitored for quality and accuracy using a risk-based monitoring approach. All sites are required to obtain and maintain local ethical approval and no additional approval was required for this analysis. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.
